# Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576

> **NCT03588026** · PHASE3 · COMPLETED · sponsor: **AKARI Therapeutics** · enrollment: 9 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** rVA576
- **OTHER:** Standard of care (SOC)

## Key facts

- **NCT ID:** NCT03588026
- **Lead sponsor:** AKARI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-07
- **Primary completion:** 2020-09-03
- **Final completion:** 2020-09-03
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03588026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03588026, "Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03588026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*